| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6649659 | GLAXOSMITHKLINE LLC | Atovaquone pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
|
US6649659 (Pediatric) | GLAXOSMITHKLINE LLC | Atovaquone pharmaceutical compositions |
Jan, 2017
(7 years ago) | |
Mepron is owned by Glaxosmithkline Llc.
Mepron contains Atovaquone.
Mepron has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Mepron are:
- US6649659
- US6649659*PED
Mepron was authorised for market use on 08 February, 1995.
Mepron is available in suspension;oral dosage forms.
Mepron can be used as treatment of pneumocystis carinii infections.
The generics of Mepron are possible to be released after 10 January, 2017.
Drugs and Companies using ATOVAQUONE ingredient
Market Authorisation Date: 08 February, 1995
Treatment: Treatment of pneumocystis carinii infections
Dosage: SUSPENSION;ORAL
How can I launch a generic of MEPRON before it's drug patent expiration?
More Information on Dosage
MEPRON family patents
